New insights into the kinetic resistance to anticancer agents

Cytotechnology

Volumn 27, Issue 1-3, 1998, Pages 225-235

  Chauffert, Bruno ^a   Marie Therese ^a   Dimanche Boitrel, ^a   Garrido, Carmen ^a   Ivarsson, Mikael ^a   Martin, Monique ^a   Martin, Francois ^a   Solary, Eric ^a  

^a INSERM   (France)

Author keywords

Anticancer drugs; Apoptosis; Cell cycle; Drug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS; CANCER CELL; CELL CYCLE; CHEMOTHERAPY; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; KINETIC RESISTANCE; ONCOGENE; RADIATION;

EID: 0032442523     PISSN: 09209069     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-017-2374-9_14     Document Type: Article

References (88)

1. Goldie JH and Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727-33.
2. Riordan JR and Ling V (1985) Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 28: 51-75.
3. Woodhouse JR and Ferry D (1995) The genetic basis of resistance to cancer chemotherapy. Ann Med 27: 157-167.
4. De Vita V (1983) The relationship between tumor mass and resistance to chemotherapy. Cancer 51: 1209-20.
5. Vukovic V and Tannock IF (1997) Influence of low pH on cytotoxicity of placlitaxel, mitoxantrone and topotecan. Br J Cancer 75: 1167-1172.
6. Valeriote F and Van Putten L (1975) Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res 3: 2619-30.
7. Dimanche-Boitrel MT, Garrido C and Chauffert B (1993) Kinetic resistance to anticancer agents. Cytotechnology 12: 347-356.
8. Liu LF (1989) DNA topoisomerase poisons as anticancer drugs. Ann Rev Biochem 58: 351-375.
9. Solary E, Bertrand R and Pommier Y (1994) Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leukemia and Lymphoma 15: 21-32.
10. Donaldson KL, Goolsby GL and Wahl AF (1994) Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 57: 847-855.
11. Tannock IF (1978) Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 62: 1117-1133.
12. Tannock IF (1994) Principles of cell proliferation: cell kinetics, In Kirkwood, JM, Lotze MT and Yasko JM (eds) Current Cancer Therapeutics, pp. 3-13. Princeton Academic Press, Princeton, New Jersey.
13. Hartwell LH and Kastan MB (1994) Cell cycle control and cancer. Science 266: 1821-1828.
14. Morgan DO (1995) Principles of CDK regulation. Nature 374: 131-134.
15. Sherr CJ and Roberts JM (1995) Inhibitors of mammalians G1 cyclin-dependent kinases. Genes Dev. 9: 1149-1163.
16. Weinberg RA (1996) E2F and cell proliferation: a world turned upside down Cell 85: 457-459.
17. Kuzminov A (1995) Collapse and repair of replication forks in Escherichia coll. Mol Microbiol 16: 373-384.
18. Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW and Pommier Y (1996) Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon cancer cells. Cancer Res 56: 4430-4437.
19. D'Arpa P, Beardmore C and Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50: 6919-6924.
20. Paulovich AG, Toczyski DP and Hartwell LH (1997) When checkpoints fail. Cell 88: 315-321.
21. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
22. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R and Harris CC (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acid Res 22: 3551-3555.
23. Me Gowan CH and Russel P (1993) Human Weel kinase inhibits cell division by phosphorylating p34 exclusively on tyr15. EMBOJ 12: 75-85.
24. Konopa J (1988) G2 Block induced by DNA crosslinking agents and its possible consequences. Biochem Pharmacol 37: 2303-2309.
25. Russell KJ, Wiens LW, Demers GW, Galloway DA, Plon SE and Groudine M (1995) Abrogation of the G2 check-point results in different radiosensitization of G1-checkpointdeficient and G1-checkpoint competent cells. Cancer Res 55: 1639-1642.
26. Dubrez L, Goldwasser F, Genne P, Pommier Y and Solary E (1995) The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 9: 1013-1024.
27. Graeber AJ, Osmanian C, Jack T, Housman DE, Koch CJ, Lowe S W and Graccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379: 88-91.
28. Ucker DS (1991) Death by suicide: one way to go in mammalian cell development. New Biologist 3: 103-109.
29. Lazebnik YA, Takahashi A, Moir RD, Goldman RD, Poirier GG, Kaufmann SH and Earnshaw WC (1995) Studies of the lamin proteinase reveal multiple parallel biochemical pathway during apoptotic execution. Proc Natl Acad Sci USA 92: 9042-9046.
30. Evans DL, Tilby M and Dice C (1994) Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the level of drug accumulation and DNA adduct formation. Cancer Res 54: 1596-1603.
31. Chen G, Shi L, Lichtfield DW and Greenberg AH ( 1995) Rescue from granzyme B-induced apoptosis by Weel kinase. J Exp Med 181:2295-2300.
32. Lahti JM (1995) PILSTRE protein kinase activity is associated with apoptosis. Mol Cell Biol 15: 1-11.
33. Shimizu T, O'Connor PM, Kohn KW and Pommier Y (1995) Unscheduled activation of cyclinB1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 55: 228-231.
34. Meikrantz W, Gisselbrecht S, Tam S and Schlegel R (1994) Activation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci USA 91: 3754-3758.
35. Yonish Rouach E (1993) P53-mediated cell death: relationship to cell cycle control. Mol Cell Biol 13: 1415-1423.
36. White E, Cipriani R, Sabbatini P and Denton A (1991) Adenovirus E1B 19-kDa protein overcomes the cytotoxicity of E1A proteins. J Virol 65: 2968-2978.
37. Fanidi A, Harrington E and Evan G (1992) Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359: 554-556.
38. Evan GI (1995) Apoptosis and the cell cycle. Curr Opin Cell Biol 7: 825-834.
39. Israel MA (1997) Optimizing cytotoxic responses in the absence of significant apoptosis. ASCO Education Book Spring 3-6.
40. Olive PL and Durand RE (1994) Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev 13: 121-138.
41. Kobayashi H, Man S, Kapitain SJ, Teicher BA and Kerbel RS (1993) Acquired multicellular resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 90: 3294-3298.
42. Dimanche-Boitrel M-T, Pelletier H, Genne P, Petit JM, Le Grimellec C, Canal P, Ardiet C, Bastian G and Chauffert B (1992) Confluence-dependent resistance in human colon cancer cells: Role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer 50: 677-682.
43. Kerbel RS (1994) Impact of multicellular resistance on the survival of solid tumors, including micrometastases. Invasion Metastasis 14: 50-60.
44. St Croix BS, Kapitain S, Sheehan C, Graham CH and Kerbel RS (1996) Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst 88: 1285-1296.
45. Nakayama K (1996) Mice lacking p27(Kipl) display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors. Cell 85: 707-720.
46. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685.
47. Porter P, Malone KE, Haegerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR and Roberts JM (1997) Expression of cell-cycle regulator p27Kipl and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 3: 222-225.
48. St Croix BS, Florenes VA, Rak JW, Flanangan M, Bhattacharya N, Slingerland JM and Kerbel RS (1996) Impact of the cyclin-dependent kinase inhibitor p27Kipl on resistance of tumor cells to anticancer agents. Nature Med 2: 1204-1210.
49. Bates RC, Buret A, van Helden DF, Horton MA and Burns GF (1994) Apoptosis induced by inhibition of intercellular contact.J Cell Biol 125: 403-45.
50. Boudreau N, Sympson CJ, Werb Z and Bissel MJ (1995) Suppression of ICE and apoptosis in mammary cells by extracellular matrix. Science 267: 891-893.
51. Day ML, Foster RG, Day KC, Zhao X, Humphrey P, Swanson P, Postigo AA, Zhang SH and Dean DC (1997) Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway. J Biol Chem 272: 8125-8128.
52. Koyama H, Raines EW, Bornfeldt KE, Roberts JM and Ross R (1996) Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors. Cell 87: 1069-1078.
53. Meredith JE and Schwartz MA (1997) Integrins, adhesion and apoptosis. Trends Cell Biol 7: 146-150.
54. Meredith JE, Fazeli B and Schwartz MA (1993) The extracellular matrix as a cell survival factor. Mol Biol Cell 4: 953-961.
55. Rak J, Mitsuhashi Y, Erdos V, Huang S-n, Filmus J and Kerbel RS (1995) Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. J Cell Biol 131: 1587-1598.
56. Kroemer G (1997) The protooncogene bcl-2 and its role in regulating apoptosis. Nature Med 3: 614-620.
57. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G and Castle VP (1995) Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 55: 2576-2582.
58. Strobel T, Swanson L, Korsmeyer S and Cannistra SA (1996) BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc natl Acad Sci USA 93: 14094-14099.
59. Jacobson MD, Burne JF and Raff MC (1994) Programmed cell death and Bcl-2 protection in the absence of a nucleus. EMBO J 13: 1899-1910.
60. Micheau O, Solary E, Hammann, Martin F and DimancheBoitrel MT (1997) Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 89: 783-789.
61. Newmeyer DD, Farschon DM and Reed JC (1994) Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 79: 353-364.
62. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP and Guyotat D (1993) High expression of Bcl-2 protein in acute myeloblastic leukemia cells is associated with poor response to chemotherapy. Blood 81: 3091-3096.
63. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Norling S and Reed JC (1995) Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471-4478.
64. Simonian PL, Grillot DAM, Merino R and Nunez G (1996) Bax can antagonize Bel-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bel-XL. J Biol Chem 271: 22764-22772.
65. Yin DX and Schimke RT (1995) BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 55: 4922-4928.
66. Li GC and Hahn GM ( 1978) Ethanol-induced tolerance to heat and to adriamycin. Nature 274: 699-701.
67. Wallner K and Li GC (1986) Adriamycin resistance and radiation response in Chinese hamster fibroblasts. Int J Radiat Oncol Biol Phys 12: 829-833.
68. Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ and McGuire WL (1992) Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 52: 3648-3654.
69. Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK and Fuqua SAW (1993) The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 53: 4443-4448.
70. Samali A and Cotter TG (1996) Heat shock proteins increase resistance to apoptosis. Exp Cell Res 223: 163-170.
71. Garrido C, Mehlen P, Fromentin A, Hammann A, Assem M, Arrigo AP and Chauffert B (1996) Inconstant association between 27-kDa heat shock protein (HSP27)content and doxorubicin resistance in human colon cancer cells. Eur J Biochem 237: 653-659.
72. Richards EH, Hickey E, Weber L and Master JR (1996) Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 56: 2446-2451.
73. Huot J, Gaetan R, Lambert H, Chretien P and Landry J (1991) Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein. Cancer Res 51: 5245-5252.
74. Garrido C, Ottavi P, Fromentin A, Hammann A, Arrigo AP, Chauffert B and Mehlen P (1997) HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 57, 2661-2667.
75. Pelletier H, Millot JM, Chauffert B, Manfait M, Genne P and Martin F (1990) Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion. Cancer Res 50: 6626-6631.
76. Frankel A, Buckman R and Kerbel RS (1997) Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 57: 2388-2393.
77. Darzynkiewicz Z (1995) Apoptosis in antitumor strategies: modulation of cell cycle or differentiation. J Cell Biochem 58: 151-159.
78. Garrido C, Chauffert B, Pinard D, Tibaut F, Genne P, Assem M and Dimanche-Boitrel MT (1995) Circumvention of confluence-dependent resistance in a human multidrug resistant colon cancer cell line. Int J Cancer 61: 873-879.
79. Toffoli G, Corona G, Gigante M and Boiocchi M (1996) Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo colon cancer cell line. Eur J Cancer 32: 1591-1597.
80. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA and O'Connor PM (1996) UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88: 956-965.
81. Powell SN, DeFrank JS, Conell P, Eogan M, Preffer F, Dombkowski D, Tang W and Friend S (1995). Differential sensitization pf p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2. delay. Cancer Res 55: 1643-1648.
82. Shinomiya N, Takemura T, Iwamoto K and Rokuntanda M (1997) Caffeine induces S-phase apoptosis in cisdiamminedichloroplatinum-treated cells, whereas cis-diamminedichloroplatinum induces a block in G2/M. Cytometry 27: 365-373.
83. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ and O'Connor PM (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxyfilline. Cancer Res 55: 1649-1654.
84. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D and Deisseroth AB (1995) High levels of constitutive WAFl/Cipl protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1: 1051-1057.
85. Vikhanskaya F, D'Incalci M and Broggini M (1995) Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int J Cancer 61: 397-401.
86. Poluha W, Poluha DK, Chang B, Crosbie NE, Schonhoff CM, Kilpatrick DL and Ross AH (1996) The cyclin-dependent kinase inhibitor p21 is required for survival of differentiating neuroblastoma cells. Mol Cell Biol 16: 1335-1341.
87. Waldman T, Lengauer C, Kinzler KW and Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381: 713-716.
88. Wang J and Walsh K (1996) Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273: 359-361.